Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

CARVYKTI (ciltacabtagene autoleucel), formerly known as cilta-cel, is chimeric antigen receptor T-cell (CAR-T) therapy indicated for the treatment of adults with relapsed or refractory multiple ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Side effects included cytokine release syndrome in 75% of patients and neurotoxicity in 14%, with some severe cases. Carvykti, a CAR-T cell therapy, is FDA-approved for patients with multiple prior ...

Biliouris also notes Carvykti’s dominant market share in the BCMA CAR-T space in the US and Germany, which reflects its appeal to both patients and physicians. Additionally, the expected growth in ...

(American Society of Hematology) Johnson & Johnson announced that the CAR T-cell therapy ciltacabtagene autoleucel (Carvykti) ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T) therapy has ...

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T ...